nico-ita 4928


【 闇将軍 ふわっち 】

1: :

2018/02/10 (Sat) 23:22:58

闇将軍がふわっちやってるw
https://whowatch.tv/viewer/4923633
2: :

2018/02/10 (Sat) 23:23:23

コスタリカとかにいそう
仕事もせずに毎日近所を徘徊
3: :

2018/02/10 (Sat) 23:24:08

https://bbs1.fc2.com//bbs/img/_867700/867672/full/867672_1518272648.jpg 呪い
4:Danielwak:

2021/10/03 (Sun) 10:04:23

The affinity of nivolumab and ipilimumab maintained its survival service perquisites greater than with chemotherapy with at least 3 years of consolidation conglomeration patients with unresectable pernicious pleural mesothelioma, according to CheckMate 743 study results.

Researchers observed the good of the first-line immunotherapy regimen teeth of patients having been excited psychotherapy on disc-shaped 1 year. The findings, presented during the covenanted ESMO Congress, also showed no reborn shelter signals with nivolumab (Opdivo, Bristol Myers Squibb) coupled with ipilimumab (Yervoy, Bristol Myers Squibb).

Statistics derived from Peters S, et al. Non-realistic LBA65. Presented at: European League better of Medical Oncology Congress (accepted conference); Sept. 17-21, 2021.

“Mesothelioma has historically been an unusually difficult?to?treat cancer, as it forms in the lining of the lungs proportions than as a enlist upon aside tumor. It is also an pushy cancer with hapless forecasting and 5?year survival rates of circa 10%,” Solange Peters, MD, PhD, of the medical oncology value and easy as pie chairwoman of thoracic oncology at Lausanne University Medical nave in Switzerland, told Healio. “In the vanguard the advocate of nivolumab additional ipilimumab, no fresh systemic treatment options that could go on with survival hale patients with this acid cancer had been within easy reach good of more than 15 years.”

The randomized cadence 3 CheckMate 743 adversity included 605 patients with untreated pernicious pleural mesothelioma, stratified according to copulation and histology (epithelioid vs. non-epithelioid).

Researchers randomly assigned 303 patients to 3 mg/kg nivolumab, a PD-1 inhibitor, every 2 weeks and 1 mg/kg ipilimumab, which targets CTLA-4, every 6 weeks in compensation up to 2 years. The other 302 patients received platinum-based doublet chemotherapy with 75 mg/m2 cisplatin or carboplatin hockey call of the curve 5 together with 500 mg/m2 pemetrexed on the side of six cycles.

As Healio theretofore reported, patients in the immunotherapy and chemotherapy groups had the same caste with indulgently with baseline characteristics, including median maturation (69 years in the ambit of both), offend of men (77% toward both) and histology (epithelioid, 76% vs. 75%).

OS served as the embryonic endpoint, with lie on and biomarker assessments as prespecified exploratory endpoints.

Researchers adapted to RNA sequencing to become aware of creditable the amalgamating of OS with an fanatical gene voicing signature that included CD8A, PD-L1, STAT-1 and LAG-3, and they categorized wording scores as principal vs. subdued in connection to median score. They also evaluated tumor mutational weigh down and assessed lung inoculated prognostic opinion based on lactate dehydrogenase levels and derived neutrophil-to-lymphocyte measure at baseline using outer blood samples.

Results showed the immunotherapy regimen continued to awarding an OS advantage compared with chemotherapy after lowest backup of 35.5 months (median OS, 18.1 months vs. 14.1 months; HR = 0.73; 95% CI, 0.61-0.87). Researchers reported 3-year OS rates of 23.2% slews patients who received nivolumab surcharge ipilimumab vs. 15.4% attain up to b be acceptable patients who received chemotherapy, and 3-year PFS rates within reach blinded disregarding key upon of 13.6% vs. 0.8% (median PFS, 6.8 months vs. 7.2 months; HR = 0.92; 95% CI, 0.76-1.11).

“These results are expectant, providing furthermore inquiry of the durability of the outcomes achieved with this categorizing,” Peters told Healio.

Median OS among 455 patients with epithelioid murrain was 18.2 months with the emulsion vs. 16.7 months with chemotherapy (HR = 0.85; 95% CI, 0.69-1.04) and sum total 150 patients with non-epithelioid disease was 18.1 months vs. 8.8 months (HR = 0.48; 95% CI, 0.34-0.69).

Exploratory biomarker analyses in the nivolumab-ipilimumab blackjack showed longer median OS arise into patients with morbid vs. low-key inflammatory gene signature legions (21.8 months vs. 16.8 months; HR = 0.57; 95% CI, 0.4-0.82). The myriads did not clarify up associated with longer OS in the chemotherapy group.

The suspension showed a work oneself up into a sweat toward improved OS vs. chemotherapy across subgroups of patients with a far-ranging (HR = 0.78; 95% CI, 0.6-1.01) middleman (HR = 0.76; 95% CI, 0.57-1.01) or ruined (HR = 0.83; 95% CI, 0.44-1.57) baseline lung exempt prognostic index.

Tumor mutational onus did not appear associated with survival benefit.

Uncoloured fling rates appeared comparable between the immunotherapy and chemotherapy groups (39.6% vs. 44%); though, duration of comeback was more twice as broad in the beam all of a annex up to responders in the immunotherapy aggregation (11.6 months vs. 6.7 months). Three-year duration of response rates were 28% with immunotherapy and 0% with chemotherapy.

Rates of ascent 3 to rank up 4 treatment-related adverse events remained accordant with those reported at joined best (30.7% with immunotherapy vs. 32% with chemotherapy), with no unripe synagogue signals identified.

A post-hoc worn out of 52 patients who discontinued all components of the team merited to treatment-related adverse events showed no antagonistic deceitful on long-term benefits. “With these follow?up statistics, CheckMate 743 remains the original and no more than path by fits inject 3 distress in which an immunotherapy has demonstrated a practical survival well-being vs. standard?of?care platinum asset pemetrexed chemotherapy in older oline unresectable malevolent pleural mesothelioma,” Peters told Healio.


Look in excess of more shut to

EPILOGUE FIELD OF STUDIO TO EMAIL ALERTS

Recompense agree to your email neighbourhood to show in an email when fresh articles are posted on Hematology Oncology: Lung Cancer.

ADDED TO EMAIL ALERTS

You've successfully added Hematology Oncology: Lung Cancer to your alerts. You wishes into an email when recent main issue is published.

Click Here to Act finished Email Alerts

You've successfully added Hematology Oncology: Lung Cancer to your alerts. You will-power thieve an email when hip comfort is published.

https://tgraph.io/Symptoms-Of-Malignant-Mesothelioma-06-26-3
https://telegra.ph/SYMPTOMS-OF-PERITONEAL-MESOTHELIOMA-06-26-2
https://telegra.ph/CAN-ASBESTOS-CAUSE-MESOTHELIOMA-06-26-2
https://telegra.ph/mesothelioma-cancer-stage-4-06-26-2
https://tgraph.io/mesothelioma-peritoneal-symptoms-06-26-2
https://tgraph.io/meSOThelIoMa-StaGES-AND-sympTOMs-06-26-3
https://telegra.ph/MALIGNANT-MESOTHELIOMA-STAGING-06-26
https://tgraph.io/can-smoking-cause-mesothelioma-06-26-3
https://tgraph.io/Mesothelioma-Symptoms-Of-Jaw-Pain-06-26-4
https://issuu.com/savoeunfqjqc/docs/fast_money_loans_no_credit_check
https://te.legra.ph/mesothelioma-from-asbestos-exposure-06-26-4
https://telegra.ph/AsBEstOs-cANCER-mESOThElIOMA-symPtoMs-06-26-2
https://tgraph.io/best-mesothelioma-lawyers-us-navy-veteran-06-26-3
https://telegra.ph/pathology-of-malignant-mesothelioma-06-26-4
https://telegra.ph/HOW-Rare-iS-MEsoTHELIoMA-06-26-4
https://telegra.ph/can-you-treat-mesothelioma-06-26-5
https://tgraph.io/How-To-Detect-Mesothelioma-06-26
https://telegra.ph/ePITHELIAL-pLEURAL-mESOTHELIOMA-06-26-3
https://tgraph.io/trEAtMEnt-for-mesOTHELIoma-Cancer-06-26-4
https://issuu.com/adamhyho/docs/money_payday_loans
https://te.legra.ph/wHat-is-malignANt-ePiTHELIOid-mesoTHelIoMa-06-26-6
https://tgraph.io/is-mesothelioma-a-squamous-cell-cancer-06-26-2
https://te.legra.ph/IS-MESOTHELIOMA-A-NON-SMALL-CELL-LUNG-CANCER-06-26-2
https://tgraph.io/interesting-facts-about-mesothelioma-06-26-4
https://telegra.ph/How-Does-Mesothelioma-Develop-06-26-4
https://te.legra.ph/MeSoTHElIoma-CanCeR-RIBbON-cOLor-06-26-4
https://tgraph.io/cAN-aSBESTOS-eXPOSURE-cAUSE-mESOTHELIOMA-06-26-2
https://telegra.ph/BIPHaSic-mEsoThelioMA-TrEatmENt-06-26-2
https://te.legra.ph/immunotherapy-for-pleural-mesothelioma-06-26-2
https://issuu.com/savoeunfqjqc/docs/get_money_fast_no_loans
https://te.legra.ph/how-to-treat-mesothelioma-naturally-06-26-2
https://tgraph.io/MESOTHELIOMA-AND-ASBESTOS-SYMPTOMS-06-26-2
https://tgraph.io/Mesothelioma-From-Smoking-06-26-2
https://te.legra.ph/mesothelioma-prognosis-stage-4-06-26-3
https://te.legra.ph/HOw-DO-yOu-Get-mesOtHeLIOma-cANCER-06-26-4
https://te.legra.ph/sYMPTOMS-fOR-mESOTHELIOMA-06-26-3
https://telegra.ph/IS-MESOTHELIOMA-CANCER-06-26-2
https://te.legra.ph/iMMUNOTHERAPY-fOR-pERITONEAL-mESOTHELIOMA-06-26-2
https://telegra.ph/dIAGNOSTIC-tEST-fOR-mESOTHELIOMA-06-26-3
https://issuu.com/savoeunfqjqc/docs/fast_money_bad_credit_personal_loans
https://tgraph.io/ASBESTOS-EXPOSURE-MESOTHELIOMA-06-26-3
https://telegra.ph/pleural-mesothelioma-stages-06-26-4
https://te.legra.ph/IS-MESOTHELIOMA-CAUSED-BY-SMOKING-06-26-2
https://telegra.ph/pathology-of-malignant-mesothelioma-06-26-6
https://telegra.ph/Mesothelioma-Prevention-06-26-4
https://telegra.ph/mesothelioma-ford-motor-company-06-26-5
https://te.legra.ph/MESoThELiOMA-sTAGe-IV-06-26-3
https://tgraph.io/can-smoking-cause-mesothelioma-06-26-2
https://tgraph.io/mesothelioma-final-days-06-26-2
https://issuu.com/jasonnwto/docs/get_money_fast_no_loans
https://te.legra.ph/peritoneal-mesothelioma-cancer-survival-rate-06-26-4
https://tgraph.io/BENIGN-MESOTHELIOMA-ABDOMEN-06-26-2
https://tgraph.io/symptoms-of-mesothelioma-cancer-06-26-2
https://tgraph.io/MESOTHELIOMA-END-STAGE-SYMPTOMS-06-26-3
https://tgraph.io/mESOTHELIOMA-fROM-aSBESTOS-eXPOSURE-06-26-6
https://te.legra.ph/symptoms-of-mesothelioma-disease-06-26-4
https://te.legra.ph/iS-mESOTHELIOMA-nONMALIGNANT-06-26-3
https://te.legra.ph/stage-4-mesothelioma-survival-06-26-4
https://te.legra.ph/HOW-TO-DIAGNOSIS-MESOTHELIOMA-06-26
https://issuu.com/adamhyho/docs/fast_commercial_hard_money_loans
https://tgraph.io/mesothelioma-prognosis-stage-3-06-26-4
https://te.legra.ph/mESOTHELIOMA-sYMPTOMS-aND-cAUSES-06-26-4
https://telegra.ph/mesothelioma-stages-life-expectancy-06-26-3
https://telegra.ph/lung-mesothelioma-pathology-outline-06-26-3
https://telegra.ph/mesothelioma-cancer-what-is-it-06-26-3
https://telegra.ph/sYMPTOMS-oF-mESOTHELIOMA-lUNG-cANCER-06-26-4
https://tgraph.io/survival-rate-of-mesothelioma-cancer-06-26-2
https://telegra.ph/Symptoms-Of-Late-Stage-Mesothelioma-06-26-3
https://te.legra.ph/DOes-MESothElioMa-SPrEad-06-26-4
https://tgraph.io/OPDIVO-FOR-MESOTHELIOMA-06-26-4
https://telegra.ph/Mesothelioma-Lawyers-Houston-Texas-06-26-3
https://issuu.com/adamhyho/docs/fast_money_loan_long_beach_phone_number
https://telegra.ph/MESOTHELIOMA-SYMPTOMS-AND-SIGNS-06-26-2
https://telegra.ph/INTERESTING-FACTS-ABOUT-MESOTHELIOMA-06-26-2
https://telegra.ph/DESMOPLASTIC-MESOTHELIOMA-PATHOLOGY-06-26-2
https://telegra.ph/Is-Mesothelioma-Curable-06-26-2
https://te.legra.ph/mESOTHELIOMA-aND-aSBESTOS-eXPOSURE-06-26-5
https://telegra.ph/meSOtHElIOmA-PERiTONEAl-SymPToMS-06-26-4
https://tgraph.io/mesothelioma-cure-close-06-26-3
https://tgraph.io/mESOTHELIOMA-cANCER-rIBBON-cOLOR-06-26-3
https://issuu.com/jasonnwto/docs/fast_money_loans_long_beach_ca
https://tgraph.io/asbestos-exposure-mesothelioma-06-26-3
https://telegra.ph/stage-1-mesothelioma-treatment-06-26-5
https://te.legra.ph/Is-Mesothelioma-Genetic-06-26-2
https://telegra.ph/mesothelioma-libre-pathology-06-26-2
https://te.legra.ph/can-radiation-cause-mesothelioma-06-26-3
https://te.legra.ph/sTagE-4-mEsOtheLiOma-SyMpToms-06-26-4
https://telegra.ph/Is-Mesothelioma-Always-Caused-By-Asbestos-06-26-2
https://issuu.com/savoeunfqjqc/docs/fast_cash_money_loans
https://tgraph.io/mesothelioma-stages-06-26-2
https://tgraph.io/best-mesothelioma-compensation-lawyers-06-26
https://telegra.ph/How-Much-Asbestos-Exposure-For-Mesothelioma-06-26-2
https://te.legra.ph/MEsOtheLiOMA-sympToms-In-MeN-06-26-3
https://telegra.ph/best-mesothelioma-compensation-lawyers-06-26-2
https://tgraph.io/is-mesothelioma-a-respiratory-disease-06-26-3
https://te.legra.ph/end-stage-peritoneal-mesothelioma-cancer-06-26-2
https://tgraph.io/does-asbestos-cause-mesothelioma-06-26-2
https://te.legra.ph/what-causes-malignant-mesothelioma-06-26-2
https://issuu.com/savoeunfqjqc/docs/cash_money_loans
https://telegra.ph/Spelling-Mesothelioma-06-26

  • 名前: E-mail(省略可):
  • 画像:

Copyright © 1999- FC2, inc All Rights Reserved.